Screener
ANI Pharmaceuticals ANIP EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net Income | $24,711 | $8,549 | $54,203 | $24,230 |
| Dividends on Series A Convertible Preferred Stock | — | (407) | — | (813) |
| Net Income Available to Common Shareholders | $24,711 | $8,142 | $54,203 | $23,417 |
| Basic and Diluted Income Per Share: | ||||
| Basic Income Per Share | $1.09 | $0.37 | $2.40 | $1.07 |
| Diluted Income Per Share | $1.05 | $0.36 | $2.32 | $1.05 |
| Basic Weighted-Average Shares Outstanding | 21,158 | 19,834 | 21,036 | 19,721 |
| Diluted Weighted-Average Shares Outstanding | 21,915 | 20,308 | 21,785 | 20,177 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's EPS (basic)?
- ANI Pharmaceuticals (ANIP) reported EPS (basic) of $1.09 in Q2 2026.
- How has ANI Pharmaceuticals's EPS (basic) changed year-over-year?
- ANI Pharmaceuticals's EPS (basic) increased by 194.6% year-over-year, from $0.37 to $1.09.
- What is the long-term trend for ANI Pharmaceuticals's EPS (basic)?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's EPS (basic) has grown at a 0.7% compound annual growth rate (CAGR), from -$3.40 to $3.50.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about ANI Pharmaceuticals's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude